Yeluri Formulations Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Yeluri Formulations Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $1.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Yeluri Formulations Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $1.9M Trade | TransData Nexus

Yeluri Formulations Private Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $1.9M Total Trade · DGFT Verified

Yeluri Formulations Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.9M across 2 products in 2 therapeutic categories. Based on 39 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Metronidazole ($1.6M), Ivermectin ($234.3K), .

Yeluri Formulations Private Limited — Export Portfolio & Destination Treemap

Yeluri Formulations Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Yeluri Formulations Private Limited? — Company Overview & Market Position

Yeluri Formulations Private Limited, established on January 15, 1997, is a privately held pharmaceutical company headquartered in Hyderabad, Telangana, India. The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. It operates under the Corporate Identification Number (CIN) U24230TG1997PTC026188 and is registered with the Registrar of Companies, Hyderabad.

As of March 28, 2024, Yeluri Formulations reported an authorized capital of ₹3.15 crore and a paid-up capital of ₹2.33 crore. The company employs approximately 86 professionals. The latest Annual General Meeting (AGM) was held on September 30, 2024, with the balance sheet filed on March 31, 2024.

What Does Yeluri Formulations Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Metronidazole$1.6M 2Ivermectin$234.3K

Product Portfolio — Top 2 by Export Value

Yeluri Formulations Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Metronidazole	Advanced Antibiotics	$1.6M	33	0.8%	15
2	Ivermectin	Antimalarial & Antiparasitic	$234.3K	6	2.7%	8

Yeluri Formulations Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $1.9M. The top category is Advanced Antibiotics (87.6% of portfolio), followed by Antimalarial & Antiparasitic (12.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Yeluri Formulations Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Yeluri Formulations operates manufacturing facilities in Hyderabad, Telangana, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding plant capacities and specialized manufacturing capabilities are not publicly disclosed.

3Key Leadership

The leadership team at Yeluri Formulations includes:

Yeluri Hari Prasad – Managing Director, appointed on April 1, 2009.
Eluri Nageswara Rao – Director, appointed on April 1, 2009.
Eluri Sridevi – Director, appointed on April 1, 2009.
Manogna Yeluri – Additional Director, appointed on June 28, 2021.

These individuals play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Yeluri Formulations Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Yeluri Formulations has engaged in exporting its pharmaceutical products to various international markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's export data from 2022 to 2026 indicates a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. Notably, the top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. However, specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly available.

2Emerging Markets

Yeluri Formulations has also extended its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's export data from 2022 to 2026 reflects a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. While the company's engagement in these regions suggests a strategic focus on emerging markets, specific details regarding WHO prequalification or other certifications enabling access to these markets are not publicly disclosed.

3Geographic Strategy

Yeluri Formulations Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Yeluri Formulations' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company's export data from 2022 to 2026 indicates a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. However, without specific regulatory filings and approvals, it is challenging to assess the company's standing in the U.S. market.

2WHO & EU GMP

Specific information regarding Yeluri Formulations' WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The company's export data from 2022 to 2026 indicates a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. However, without access to specific certifications, it is difficult to evaluate the company's compliance with international quality standards.

Yeluri Formulations Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Yeluri Formulations operates in the competitive pharmaceutical industry, focusing on finished formulations such as tablets, capsules, syrups, and injections. The company's export data from 2022 to 2026 indicates a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. While specific market share comparisons and head-to-head analyses with competitors are not publicly available, the company's product portfolio and export activities suggest a presence in the global pharmaceutical market.

2Key Differentiators

Yeluri Formulations' key differentiators include its focused product portfolio, with the top five products accounting for 100% of exports, and its engagement in both regulated and emerging markets. The company's export data from 2022 to 2026 indicates a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. These factors highlight the company's strategic approach to market penetration and product specialization.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Yeluri Formulations Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Yeluri Formulations has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $1.9 million USD across 39 shipments from 2022 to 2026. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. This consistency indicates reliability in fulfilling export commitments. However, specific indicators of reliability, such as on-time delivery rates and customer satisfaction metrics, are not publicly disclosed.

2Certifications to Verify

Importers should verify the following certifications when considering Yeluri Formulations as a supplier:

FDA Approval: Confirm that the company's products are

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Yeluri Formulations Private Limited

How many pharmaceutical products does Yeluri Formulations Private Limited export from India?

Yeluri Formulations Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Metronidazole ($1.6M), Ivermectin ($234.3K). Total export value is $1.9M.

What is Yeluri Formulations Private Limited's total pharmaceutical export value?

Yeluri Formulations Private Limited's total pharmaceutical export value is $1.9M, based on 39 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Yeluri Formulations Private Limited cover?

Yeluri Formulations Private Limited exports across 2 therapeutic categories. The largest are Advanced Antibiotics (87.6%, 1 products), Antimalarial & Antiparasitic (12.4%, 1 products).

Get Full Yeluri Formulations Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.